| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6113718 | Critical Reviews in Oncology/Hematology | 2013 | 10 Pages |
Abstract
Pralatrexate, anti-CD30 monoclonal antibodies, brentuximab vedotin (SGN-35) in particular, 131I-anti-CD45 radioantibody, yttrium-anti-CD25 radioimmunoconjugates, histone deacetylase inhibitors, bortezomib, gemcitabine, vorinostat, lenalidomide, and their combinations represent the most appealing chemotherapy and/or targeted agents to be investigated in future trials.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Andrés J.M. Ferreri, Silvia Govi, Stefano A. Pileri, Kerry J. Savage,